Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02633 JACOBSON PHARMA
RTNominal unchange0.570 0.000 (0.000%)
Others

23/07/2019 09:57

Jacobson Pharma (02633) to buy 43% of medicine business

[ET Net News Agency, 23 July 2019] Jacobson Pharma Corporation Limited (02633) said its
subsidiary Sampan Development Limited (the purchaser) has agreed to buy 43% of the issued
share capital of Orizen Capital Limited (the target) at an aggregate consideration of
HK$113.38 million. Immediately after completion, the target will be held as to 88% by the
purchaser.
The target is principally engaged in the proprietary Chinese medicine business. The
acquisition represents a compelling opportunity to accelerate the group's strategy in
enhancing the portfolio of its proprietary medicine business. It lays the foundation to
create a leading branded Chinese medicine business which will be well-positioned to
deliver strong sales, cash-flow and earnings growth for the group. (RC)

Back to Others

Remark: Real time quote last updated: 19/04/2024 15:49
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.